HHS Safe Harbor: Regulatory Outlook in the Age of Uncertainty
Over 20,000 comments have been submitted by industry to the proposed changes to the HHS Safe Harbor Rule. No topic affecting the pharmaceutical industry today has insiders talking as much as these changes, which affect point-of-care rebates for biopharma products.
You need to understand the ins and outs of the proposed new Safe Harbors as well as strategies for pricing so your company can not only comply with the rule, but also leverage it to build competitive advantage.
Download this presentation by Model N’s legal expert John Shakow for a deep dive into:
- Content and details of the proposed HHS Safe Harbor Rule changes
- Implications of the newfound focus on prices at the pharmacy to the flow of dollars in the supply chain, and the hanging nature of rebates and chargebacks and how they are used.
Learn what you can do today to prepare for changes to Safe Harbor. Download the presentation today.